Aurélie Veugeois

Early outcome of degenerated self-expandable sutureless aortic prostheses treated with transcatheter valve implantation: A pilot series

From the Cardiology Department and Cardiac Surgery Department, Institut Mutualiste Montsouris, Paris, France. Disclosures: C.C. is a proctor for Medtronic. All other authors have nothing to disclose with regard to commercial support. Received for publication June 6, 2016; revisions received July 12, 2016; accepted for publication July 24, 2016. Address for reprints: Nicolas Amabile, MD, PhD, Department of Cardiology, Institut Mutualiste Montsouris, 42 Blvd Jourdan, 75014 Paris, France (E-mail: nicolas.amabile@imm.fr). J Thorac Cardiovasc Surg 2016;-:1-3 0022-5223/

Combined Structural Heart Disease Interventions to Treat a Failed Bioprosthesis: The Janus Procedure

36.00 Copyright 2016 by The American Association for Thoracic Surgery http://dx.doi.org/10.1016/j.jtcvs.2016.07.079

Transcatheter Aortic Valve Replacement for Severe Aortic Regurgitation With Acute Refractory Cardiogenic Shock

An 81-year-old woman was referred to our center for severe aortic regurgitation (AR) related to bioprosthesis degeneration. She initially had an ascending aortic aneurysm with symptomatic AR and underwent surgical implantation of a Trifecta 21-mm prosthesis (St. Jude Medical, St. Paul, Minnesota),

Radiotherapy-induced vascular damage in mammary arterial graft: correlations between optical coherence tomography and pathology

From January 2013 to January 2017, 686 consecutive patients were referred to our centre for transcatheter aortic valve replacement, including 5 subjects with severe aortic regurgitation and acute refractory cardiogenic shock. These patients were contraindicated for surgical treatment by the heart team because of high surgical risk (median logistic EuroSCORE: 74.6/Society of Thoracic Surgeons score: 37.9). The success rate of valve implantation was 100% through transfemoral access with self-expandable devices. The observed 30-day mortality rate was 20%. Hence, the transcatheter aortic valve replacement procedure might represent a successful and life-saving intervention for treatment of patients with severe aortic regurgitation who present with acute refractory cardiogenic shock.

0354: Paravalvular aortic regurgitations with SAPIEN 3 prosthesis lowest seen with balloon-expandable TAVR

A 53-year-old man with a previous history of mediastinal radiotherapy was referred to our institution for coronary artery bypass graft and aortic valve replacement. Per-operative surgical analysis revealed poor flow within left and right internal mammary arteries (LIMA and RIMA), making their use as peducunlated conduits unsuitable. The proximal end arteries were removed and both vessels were harvested as free grafts. …

0345: Thirty-day outcomes of transcatheter aortic valve implantation with the latest generation Edwards SAPIEN 3 prosthesis via the transiliofemoral approach

Background Paravalvular aortic regurgitation (PAR) after TAVR has been associated with increased mortality. The Sapien 3 device (Edwards Life-sciences) is different than the prior devices released by the same manufacturer in that it has a skirt designed to prevent paravalvular leak, improved coaxial alignment, and more accurate positioning. Aims To evaluate paravalvular aortic regurgitations after 30-day after TAVI using the Edwards SAPIEN 3 prosthesis. Methods Prospective monocentric study including 66 high-risk or non-operable patients with severe aortic stenosis undergoing TAVI using Edwards SAPIEN 3 prosthesis via transfemoral access, between September 2014 and March 2015. Results Mean age of patient was 84±7,1 years (70% female). The MDCT estimated an aortic annular diameter 25,07±2mm. Mean logistic EuroSCORE was 15,8±10,8. In our study, the device success rate was 98.5%. The pros-thesis has been deployed correctly in all cases and no failure of valve or embolization had occurred. Post TAVR, mean transaortic gradient decreased from 46,0±12,33mmHg to 8,2±3,37mmHg (p Conclusion In our study, TAVI with Edwards SAPIEN 3 demonstrated lower paravalvular aortic leak rates than earlier generation devices in patients at high risk for surgery.

Feasibility limits of transradial primary percutaneous coronary intervention in acute myocardial infarction in the real life (TRAP-AMI).

Background Few data is available concerning the latest generation Edwards SAPIEN 3- S3 in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI). Aims To evaluate periprocedural and 30-day clinical outcomes of TAVI using the Edwards SAPIEN 3 prosthesis) via transiliofemoral approach. Methods Between September 2014 and March 2015, consecutive high-risk or non-operable patients with severe aortic stenosis had TAVI using Edwards SAPIEN 3 prosthesis in Institut Mutualiste Montsouris. Valve Academic Research Consortium endpoints were used. Results Of 142 patients who underwent TAVI using Edwards SAPIEN prosthesis, 66 were treated with SAPIEN 3 via transfemoral access (mean age 84±7.1 years; 70% female). About 65% and 48% of patients had, respectively, severe peripheral artery diseases and calcified iliofemorale arteries. Multi-detector computed tomography estimated an aortic annular diameter of 25,07±2mm. Mean logistic EuroSCORE was 15,8±10,8. The device success rate was 98.5%. No failure of valve deployment had occurred and no patient had more than mild paravalvular aortic regurgitation. Mean transaortic gradient decreased from 46, 0±12,33mmHg to 8,2±3,37mmHg (p Conclusion In our study, TAVI with Edwards SAPIEN 3 was associated with a high rate of device success and low rate of paravalvular aortic regurgitations and major bleedings.